ストックスクリーナーアプリを入手
0.79
19.29%
-0.1888
前日終値:
$0.9788
開ける：
$0.8915
24時間の取引高:
711.63K
Relative Volume:
5.89
時価総額：
$30.83M
収益：
$135.87M
当期純損益:
$72.20M
株価収益率:
0.5563
EPS:
1.42
ネットキャッシュフロー:
$45.09M
1週間 パフォーマンス:
-16.14%
1か月 パフォーマンス:
-13.43%
6か月 パフォーマンス:
-34.17%
1年 パフォーマンス:
-67.22%
1日の値動き範囲:
$0.75
$0.8915
1週間の範囲:
$0.75
$0.99
52週間の値動き範囲:
$0.7284
$3.07
Scynexis Inc Stock (SCYX) Company Profile
SCYX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SCYX
Scynexis Inc
|
0.79 | 36.76M | 135.87M | 72.20M | 45.09M | 1.42 |
|
HLN
Haleon Plc Adr
|
10.80 | 48.39B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
163.04 | 70.91B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.85 | 3.54M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.11 | 45.20B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.94 | 19.42B | 16.54B | -1.64B | 749.00M | -1.45 |
Scynexis Inc Stock (SCYX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-01-22 | 開始されました | Guggenheim | Buy |
| 2021-01-06 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-07-11 | アップグレード | Needham | Hold → Buy |
| 2018-06-27 | 開始されました | Maxim Group | Buy |
| 2017-10-24 | 開始されました | Guggenheim | Buy |
| 2017-07-10 | 開始されました | ROTH Capital | Buy |
| 2017-05-09 | ダウングレード | Needham | Buy → Hold |
| 2017-03-03 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2016-10-20 | 開始されました | H.C. Wainwright | Buy |
| 2016-10-07 | アップグレード | WBB Securities | Buy → Strong Buy |
| 2016-10-03 | 再開されました | Brean Capital | Buy |
| 2016-08-17 | 開始されました | Guggenheim | Buy |
| 2016-08-09 | 繰り返されました | Needham | Buy |
| 2016-08-09 | アップグレード | WBB Securities | Speculative Buy → Buy |
| 2016-03-28 | 開始されました | Brean Capital | Buy |
| 2015-12-29 | 開始されました | WBB Securities | Speculative Buy |
| 2015-11-16 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2015-06-10 | 開始されました | Needham | Buy |
| 2014-05-29 | 開始されました | Canaccord Genuity | Buy |
| 2014-05-29 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Scynexis Inc (SCYX) 最新ニュース
FDA lifts hold on Scynexis trial; Incyte’s Zynyz notches another FDA approval - Endpoints News
SCYNEXIS (NASDAQ:SCYX) Now Covered by Analysts at StockNews.com - Defense World
SCYNEXIS Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Scynexis: Q1 Earnings Snapshot - CT Insider
SCYX Reports Strong Q1 Revenue, Progress in Clinical Trials | SC - GuruFocus
SCYX: Cash Reserves and Debt Repayment Update | SCYX Stock News - GuruFocus
SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update | SCYX Stock News - GuruFocus
SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
SCYNEXIS Antifungal Drug Cleared by FDA, but GSK Partnership Hits Major Roadblock - Stock Titan
SCYNEXIS INC SEC 10-Q Report - TradingView
News - Biostock
SCYNEXIS (SCYX) Projected to Post Earnings on Wednesday - Defense World
JPMorgan Chase & Co. Makes New Investment in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World
SCYNEXIS, Inc. (NASDAQ:SCYX) Shares Sold by LPL Financial LLC - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
StockNews.com Begins Coverage on SCYNEXIS (NASDAQ:SCYX) - Defense World
Aspergillosis Market Expected to Rise by 2034, Regeneron, Pulmocide, Astellas Pharma, Cipla, Pulmatrix, F2G, Cellix Bio, SCYNEXIS, TFF, Matinas BioPharma, Amplyx Pharmaceuticals, Cidara Therapeutics, - Barchart.com
SCYNEXIS (NASDAQ:SCYX) Upgraded by StockNews.com to Hold Rating - Defense World
Blastomycosis Treatment Market Overall Study Report 2025-2032 | Janssen, Scynexis Inc, Novartis AG, Marck & Co. - openPR.com
Acute Vulvovaginal Candidiasis Treatment Market Poised - openPR.com
SCY-247 shows promise against resistant fungal infections By Investing.com - Investing.com South Africa
SCY-247 shows promise against resistant fungal infections - Investing.com
Breakthrough: SCYNEXIS's New Antifungal Drug Defeats 171 Resistant Fungal Strains in Latest Tests - Stock Titan
Aspergillosis Market on Track for Major Expansion by 2034, According to DelveInsight | F2G, Pulmatrix, TFF Pharmaceuticals, Scynexis, Pulmocide - The Globe and Mail
SCYNEXIS (NASDAQ:SCYX) Lowered to Sell Rating by StockNews.com - Defense World
SCYNEXIS (SCYX) to Release Earnings on Thursday - Defense World
Research Analysts Issue Forecasts for SCYNEXIS FY2029 Earnings - Defense World
StockNews.com Downgrades SCYNEXIS (NASDAQ:SCYX) to Sell - Defense World
SCYNEXIS Full Year 2024 Earnings: Misses Expectations - Yahoo Finance
SCYNEXIS Reports 2024 Financial Results and Updates - TipRanks
Scynexis Inc earnings beat by $0.06, revenue fell short of estimates - Investing.com Australia
SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times
SCYNEXIS, Inc. Advances Phase 1 Trial of SCY-247 Antifungal and Prepares for Phase 3 MARIO Study Restart - Nasdaq
SCYX stock touches 52-week low at $0.89 amid market challenges - Investing.com Australia
NanoNewron Appoints Industry Veteran Marco Taglietti, M.D., as Chief Executive Officer to Lead the Company and the Development of Their Promising Alzheimer’s Compound - BioSpace
EQUITY ALERT: Levi & Korsinsky, LLP Notifies Shareholders of SCYNEXIS, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 8, 2017SCYX - ACCESS Newswire
SCYNEXIS (NASDAQ:SCYX) Stock Crosses Below 200-Day Moving Average – Time to Sell? - Defense World
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of SCYNEXIS, Inc. (SCYX) Investigation - ACCESS Newswire
SCYNEXIS (NASDAQ:SCYX) Share Price Passes Below 200-Day Moving Average – Should You Sell? - Defense World
Geode Capital Management LLC Acquires 36,405 Shares of SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World
FEDERATED HERMES, INC. Reduces Stake in SCYNEXIS Inc: A Detailed Analysis - GuruFocus.com
Aspergillosis Market Expected to rise, 2034 | Regeneron, Pulmocide, Astellas Pharma, Cipla, Pulmatrix, F2G, Cellix Bio, SCYNEXIS, TFF, Matinas BioPharma, Amplyx Pharmaceuticals, Cidara Therapeutics, I - The Globe and Mail
SCYNEXIS, Inc. (NASDAQ:SCYX) Short Interest Update - Defense World
Stay Ahead in Ophthalmology: Strategic Market Insights for Myopia Assessment & Forecasting | DelveInsight - GlobeNewswire Inc.
Scynexis Inc (SCYX) 財務データ
収益
当期純利益
現金流量
EPS
0.57%
大文字化:
|
ボリューム (24 時間):